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Oral Presentations S189Methods: Retrospective analysis of voriconazole trough levels in
53 pediatric patients following allogeneic HCT receiving fungal
prophylaxis with oral or IV voriconazole. Ages ranged 0.5 to 20
years, median 14 years. Serum levels were measured by high-perfor-
mance liquid chromatography. Samples were obtained 5 to 7 days
after start or change in dose of voriconazole, 298 total levels were
evaluated.
Results:The mean age of patients with levels\0.5 mcg/ml was 6.4
years and 13 years for those with levels $ 0.5mcg/ml. Most patients
failing to achieve adequate trough levels were# 9 years of age (15/17
patients). A level of$ 0.5mcg/ml was achievable in a subset of these
patients (8/15) when the dosage was increased from 4mg/kg/dose q
12h to doses ranging from 6mg to 11 mg /kg/dose q12h. 7/15 never
achieved a level$ 0.5mcg/ml despite doses ranging from 7 to 8.2mg/
kg/dose. 2/17 patients that were# 9 years of age did achieve a level$
0.5mcg/ml with dosing of 4mg/kg/dose. Changing from oral to IV
therapy in 3 patients with low trough levels did not improve the
trough level. Multi-time point measurements were $ 0.5mcg/ml at
2 to 6 hours after oral / IV dose, but fell to 0.2mcg/ml by 12 hours
in 3 patients tested. Of 298 voriconazole levels, 156 were $ 0.5
mcg/ml.
Conclusions: Unlike reports in adult patients, we found that fre-
quent monitoring of voriconazole levels was necessary in pediatric
patients less than 10 years old receiving HCT. In addition, younger
pediatric HCT patients may require more frequent dosing schedules
to achieve trough levels or initial dosing higher than the recommen-
ded adult dosing of 4mg/kg/dose q12h.96
TREATMENT OF ADENOVIRUS (ADV) INFECTIONS RESISTANT TO CIDO-
FAVIR (C) WITH CMX001 (CMX) IN PEDIATRIC PATIENTS RECEIVING
HCT
Morris, C.L.1, Painter, W.2, Lanier, R.2, Morris, J.D.1 1Loma Linda
University Hospital, Loma Linda, CA; 2Chimerix Inc, Durham, NC;
3Redlands, CA
ADV infections early after HCT are fatal in up to 50% of patients.
CDV is commonly used to treat ADV infection, but requires i.v. ad-
ministration, has renal and marrow toxicity, and virus control is vari-
able. CMX is an orally administered lipid conjugate of CDV with
decreased toxicity and increased potency against dsDNA viruses, in-
cluding ADV. We report our experience treating 4 patients with
ADV infections after HCTwith CMXwho had developed resistance
to CDV or could not tolerate CDV. All cases had GVHD prior to
onset of infection. All had positive stool pcr (2) or culture (2) 16-
64 days after HCT followed by viremia 2-11 days later. All received
CDV for 2-8 weeks before switching to CMX. ADV responded to
CDV in 2 patients followed by re-emergence after 6 weeks therapy.
Two patients had no response to CDV, one with rising viremia dur-
ing 2 weeks of treatment. Subsequent to CDV, these patients re-
ceived oral CMX at 4mg/kg twice weekly. Three had undetectable
viremia and negative GI stool pcr/cultures after 2 weeks on CMX.
One patient died of multiorgan failure due to pre-existing liver-
lung toxicity and GVHD after 4 doses of CMX. During treatment
viremia fell from 89,000 to 19,000 copy/ml. After 4-6 weeks of unde-
tectable ADV, 2 patients had CMX dose decreased to a 1x/week.
ADV was detected within 2 weeks: 1 in stool, 1 in plasma and stool.
Return to twice weekly CMX resolved infection in 1 and 1 continues
with viremia (\500 copy/ml) and GI infection. Notably, repeat PK
study in this patient showed\half of the expected levels of CMX in
plasma. ADV typing by hexon analysis was performed on samples
from plasma, stool, and biopsies. Two had subtype 31 one also
with type 5 (dual infection), two had subtype 1. Sensitivity testing
from ADV obtained at onset of infection (type 1) before treatment
with CDV and 1 obtained after 6 weeks of treatment with CDV
(type 31) showed resistance to CDV (. 100uM type 31 and 13.4
uM type 1) and CMX (both . 0.5uM). Toxicity is difficult to assess
in these complex cases but no renal or marrow toxicity was attributed
to CMX therapy. CMX 4mg/kg once weekly was not adequate to
prevent re-emergence of ADV in our two patients with C resistant
ADV. CMX can suppress, but does not appear to eradicate ADV in-
fection in severely immune compromised patients after HCT. Out-
come depends on durable pharmacologic control of both ADVinfection and GVHD that permits eventual reduction in immune
suppression.
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A COST EFFECTIVE MARKETING TOOL IN A BLOOD AND MARROW
TRANSPLANT PROGRAM
Nista, E.J. Medical University of South Carolina, Charleston, SC
Introduction: In an effort to increase communication between re-
ferring physicians and our blood and marrow transplant physicians
an e-mail marketing plan was devised using a departmental newslet-
ter. Team members provided content and the data manager format-
ted the text. Three e-mail newsletters were created and sent over
a one year period. This newsletter provided a forum for the trans-
plant physicians to discuss referral guidelines, treatment, transplant
complications, long term sequelae and recommendations, and pro-
vide links to related research and outcomes data as well as introduce
and highlight new staff members and events of interest including
newly completed clinical areas.
The newsletter was sent to two groups. The first was physicians
who had referred patients to our institution for blood and marrow
transplant. The second group was to all other oncology physicians
in South Carolina listed in theMUSCHollings Cancer Center data-
base.
Results: Physicians who had referred in the past (n5 143) averaged
a 40.3% open rate compared to non-referring physicians (n5 1242)
who had a 16.3% open rate, (the industry average for medical ser-
vices is 16.7%). Referrals tracked during the period of time the news-
letters were sent increased 48% compared to the same time the
previous year. 5.9% of these referrals were from physicians who
had not previously referred to our institution. During this same
time period six physicians who had not referred to our institution
in four years or greater referred a minimum of two patients each.
Click through rates (people who clicked on the links for additional
information and/or related websites), averaged 8.9% forMUSC’s re-
ferring physicians, non-referring physicians clicked in at 3.7%. The
industry average click through rate was 13.3%, significantly higher.
Table 1. E-Mail Run History
Open Bounce-back Click-through
Rate Rate RateIndustry Average 16.7% 5.3% 13.3%
MUSC Average to Referring Physicians 40.3% 4.2% 8.9%
MUSC Average to All Instate Oncologists 16.3% 19.2% 3.7% All data courtesy of Constant Contact.
Conclusion: The newsletter was an excellent return on investment.
It allowed the team to put their program in front of every referring,
and potential referring, physician while not taking time away from
clinical practice.
Particularly for those physicians who have referred in the past it
was an excellent and cost effective educational and marketing tool,
increasing both referrals as well as physician to physician commu-
nication. This tool used far less of the clinical staff’s time than
alternative forms of communication, (such as phone calls and
e-mails) and, (unlike conferences, in-services or physician to
physician visits), did not require any time spent away from clinical
areas.
98
RELATION BETWEEN THE CIBMTR STANDARD FORMS AND THE EVOLU-
TION OF A TRANSPLANTATION CENTER DATABASE QUALITY AND FIDEL-
ITY
Filipi, C.F., Mauad, M.A., Simione, A.J., Testa, A L.H., Colturato, R
V.A., Souza, M.P., Vieira, J.O., Matedi, M.A.L.H., Meireles, F.S. Hos-
pital Amaral Carvalho, Jau, SP, Brazil
Introduction: The work of a data manager team is basically to get
the information in the patient’s chart written by physicians and lab
results to report on standard forms.
Objective:Understand and alert both physicians and data managers
that not always the clinical written routine of a Transplant Center is
Table 1. Clinical evolution  CIBMTR Pattern
Clinical Evolution Evaluation Method Cibmtr Pattern
Glucose 5 192mg/dL Acquired knowledgment + lab report Diabetes / hyperglycemia
Skin damage Physician and data manager discussion + lab report + acquired
knowledgment
Acute Skin GVHD, overall maxim grade II, stage 2
(25-50% of skin surface)
Mouth / GI Chronic GVHD Physician and data manager discussion + lab report + acquired
knowledgment
Chronic GVHD progressive, maximum grade: extensive,
overall severity: severe
Unremarkable mouth lichen Physician and data manager discussion + acquired knowledgment Are symptoms of chronic GVHD still present on the date
of actual contact?
Pleural effusion /
basilar consolidation
Physician and data manager discussion + acquired knowledgment Did the recipient develop non-infectious pulmonary
abnormalities?
RSV+ Lab report + acquired knowledgment Organism: RSV, Infection site: sinuses, date of diagnosis
Moderate ascites Physician and data manager discussion + lab report + acquired
knowledgment
Non-infectious liver toxicity (excluding GVHD)
S190 Oral Presentationspossible to get a conclusively and directly interpretation to be re-
ported on the standard CIBMTR data pattern.
Method: Study of a related allogeneic transplant case that we were
asked to do the Comprenhesive Report Form.
Case: Male, 53 years-old, MDS, HSCT infusion: 06/20/2009,
PBSC, HLA-identical sibling, Bu 1 Flu, ANC recovery: 05/07/
2009 and platelet recovery: 07/10/2009.
Results:Analyzing the chart, it’s seen that the interpretation of writ-
ten clinical data to the standard official CIBMTR forms requires
more than generalized information that are easily understood by
the clinical staff with their real and daily involvement with them
and the experience of practicing medicine. Data managers have
a ‘‘virtual relationship’’ with patients, no personal contact with
them and without scientific knowledgment to interpret certain infor-
mation and reports. What was concluded is that more detailed the
clinical outcome in the patient records, more support of clinical staff
and more acquired knowledgment by data managers, greater the ef-
ficiency in reporting data with a high degree of fidelity.
Feedback:During the relationship’s period between our Transplant
Center and CIBMTR we had a positive evolution of the way to deal
with transplant data. Physician’s and data managers’ relation had
global gains to our Center, working with the clinical outcome as
the primary source of data to be consulted and having footing for
this. The multidisciplinary team’s integration and the effort of the
medical directors, gave the data managers (including database per-
sonnel and a nurse) a day-by-day know-how to read clinical data
(not to interpret it, but the transcript it to CIBMTR standard) and
thus, gradually, the intervention of medical staff shall not be so nec-
essary. That is, reporting data to CIBMTR spawned to a natural evo-
lution of our Transplant Center, of the team (physicians, data
managers and nurse) and of the description and interpretation of
clinical information, resulting in the reliability of data, generating
a solid basis for prospective studies.99
PUBLICATION BIAS IN BLOOD AND MARROW TRANSPLANTATION: AN
ANALYSIS OF THE TANDEM MEETING ABSTRACTS
Paulson, K.1, Saeed, M.1, Mills, J.2, Cuvelier, G.D.E.1, Kumar, R.1,
Morcombe, K.1, Ramesar, K.1, Robinson, T.1, Szwajcer, D.1, Wall, D.1,
Watral, W.1, Seftel, M.D.1 1CancerCare Manitoba, University of Man-
itoba, Winnipeg, MB, Canada; 2Northwestern University, Chicago, IL
Background:Research studies presented in abstract formmay never
be fully published. In other areas of medicine, abstracts with positive
results are more likely to be published than negative studies, leading
to publication bias. There are limited data about the presence of pub-
lication bias in the field of blood andmarrow transplantation (BMT).
Methods: All abstracts presented at the 2006 CIBMTR/ASBMT
Tandem Meeting were categorized based on type of study (clinical
prospective or retrospective, translational, basic science, case report,
or review), and whether the results were positive, negative, or not
stated. An abstract was categorized as positive if it validated the au-
thors’ hypothesis, or if it showed that a new treatment, diagnostic
test, or procedure was useful. Two authors reviewed each abstract,
and a third author reviewed disagreements (if present). To determine
publication status, each abstract was searched on the MEDLINE
database by first and last authors.Results: 501 abstractswere reviewed. 217were published, giving a pub-
lication rate of 43%.Median time fromabstract presentation to full pub-
licationwas 19months (range 1 - 41months). 52.5%of all abstractswere
published in three journals - Biology of Blood and Marrow Transplan-
tation (19.8%), Blood (17.5%), or Bone Marrow Transplantation
(15.2%). The remaining 47.5%were published in 53 different journals,
with no one journal having more than 3% of published abstracts. Ab-
stracts that were positive were more likely to be published (50.1%)
than those that were negative (33%) or not stated (29.7%) (p5 0.001).
Clinical studies (retrospective or prospective) and translational/basic sci-
encestudiesweremore likely tobepublished thancase reportsorprimar-
ily descriptive studies (p5 0.001). Specifically, 48.5% of clinical studies
and 56.9% of basic science or translational studies were published, but
only 7.1% of descriptive or case reports were published.
Conclusion: Publication bias does exist in the field of BMT, with
positive abstracts significantly more likely to be published than neg-
ative abstracts. Full publication of negative results should be encour-
aged to provide a more balanced medical literature, and clinicians
should be aware of the existence of publication bias.PHARMACY ORAL
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OPTIMIZING THE ROLE OF TACROLIMUS BY ACHIEVING AND MAINTAIN-
ING TARGET LEVELS VIA A LOADING DOSE FOLLOWED BY A MAINTE-
NANCE DOSE AT EMORY HEALTHCARE
Ng, A., Wilson, N.M., Surati, M., Shah, K.S., Hutcherson, D.A. Emory
Healthcare, Atlanta, GA
Purpose: Graft-versus-host disease (GVHD) is a common compli-
cation associated with allogeneic hematopoietic stem cell transplants
(HSCT). Tacrolimus plays an integral role in GVHD prophylaxis.
At Emory Healthcare, the daily intravenous dose has been 0.03
mg/kg/day based on ideal body weight. Over the last two decades,
our target tacrolimus levels have gradually changed from 10 - 40
ng/mL to 6 - 12 ng/mL. However, our dosing has remained un-
changed. Due to results of a prior evaluation demonstrating that
the majority of our patients required dose reductions based on
drug levels, we implemented a 48 hour loading dose of 0.03 mg/
kg/day followed by a 0.02 mg/kg/day maintenance dose. We have
now performed an evaluation to assess the impact of this tacrolimus
dosing strategy compared to the previously studied cohort.
Method: A retrospective chart review was conducted in allogeneic
HSCT patients who received intravenous tacrolimus from May
2008 to March 2009. Data collected included height, weight, tacro-
limus doses on days - 2 through day 1 10, and tacrolimus levels on
days 0 through day1 10. This group was compared to the previously
studied cohort receiving the standard 0.03 mg/kg dose as a control.
Result: A total of 22 patients were studied. The control group of 14
patients demonstrated an average dose adjustment of 54% (25% -
96%) on days 5, 7, and 10. The study group remained at an approx-
imate average dose of 0.02 mg/kg/day for an average of 99% (50% -
200%) of the maintenance dose. Compared with the control group
which had 100% of patients achieving levels . 12 ng/mL during
days 1 through 10, the study group resulted in approximately 36%
of patients with supratherapeutic levels. The control group had
50%of patients with levels\6 ng/mL compared to 54% in the study
group.
